Why Hair Loss Starts in the Scalp, Not the Follicle
Most hair loss treatments target the follicle. The problem is upstream: poor vascularization, chronic inflammation, and fibrosis are the real culprits. Here is what the research says.
Hair loss is typically framed as a follicle problem. The follicle miniaturizes. The follicle stops producing a terminal hair. The follicle dies. The focus of most interventions — from minoxidil to DHT blockers to finasteride — is to address what is happening at or inside the follicle itself.
But there is growing evidence that by the time follicle miniaturization is visible, significant upstream damage has already occurred. The scalp environment — the blood supply, the extracellular matrix, the inflammatory milieu — is the primary driver.
The Vasculature Problem
A healthy anagen hair follicle is a metabolically demanding structure. It requires continuous delivery of oxygen, glucose, amino acids, and growth factors through a dense capillary network that surrounds the follicle base. In androgenetic alopecia (AGA), this vasculature is progressively compromised.
Studies using laser Doppler flowmetry have demonstrated reduced blood flow velocity in balding scalp regions compared to non-balding regions in the same individuals. The follicles are not failing because they are inherently defective — they are failing because they are being starved.
BPC-157 addresses this directly. Its primary mechanism in hair restoration is angiogenesis — the formation of new capillaries. It upregulates VEGF (vascular endothelial growth factor) expression and stimulates endothelial cell tube formation, essentially rebuilding the vascular infrastructure around atrophied follicles.
The Fibrosis Problem
Another under-discussed mechanism is perifollicular fibrosis — the deposition of excess collagen around the follicle that physically constricts it. In AGA, this fibrosis can reduce follicle diameter by 30–40% before any visible thinning is apparent.
The fibrosis is driven by chronic low-grade inflammation, primarily from DHT-induced TGF-β1 secretion by dermal papilla cells. TGF-β1 activates local fibroblasts to produce excess collagen, which accumulates around the follicle sheath.
TB-500 (Thymosin Beta-4) is the most effective peptide for countering this process. It upregulates MMP-2, a matrix metalloproteinase that degrades excess collagen, and suppresses the NF-κB inflammatory pathway that drives TGF-β1 production in the first place.
The Stem Cell Problem
Even with restored blood supply and reduced fibrosis, follicles cannot recover if their stem cell reservoir has been depleted. Hair follicle stem cells (HFSCs) reside in the bulge region and are responsible for initiating each new anagen cycle.
GHK-Cu's primary value is its ability to reactivate HFSCs via Wnt/β-catenin signaling. It also stimulates the proliferation of dermal papilla cells — the dermal cells that communicate with HFSCs to coordinate the follicle cycle.
Treating the Environment, Not Just the Follicle
The most effective approach to hair restoration treats all three upstream problems simultaneously:
1. Restore vascularization (BPC-157) 2. Resolve fibrosis (TB-500) 3. Reactivate stem cells (GHK-Cu)
Only once this foundation is in place does it make sense to add peptides targeting follicle neogenesis (PTD-DBM) or growth factors (IGF-1 LR3). Applying these advanced compounds to a compromised scalp environment is like planting seeds in concrete.
This is the logic behind our Foundation Routine and why its sequencing matters.